Phathom Pharmaceuticals, Inc. (PHAT) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 30 days, typically, give or take 14 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Oct 29, 2026before open 29 8-K
Q2 FY2026Thu, Jul 30, 2026before open 30 8-K
Q1 FY2026Thu, Apr 30, 2026before open 30 8-K
Q4 FY2025Thu, Feb 26, 2026before open 57 8-K
Q3 FY2025Thu, Oct 30, 2025before open 30 8-K
Q2 FY2025Thu, Aug 7, 2025before open 38 8-K
Q1 FY2025Thu, May 1, 2025before open 31 8-K
Q4 FY2024Thu, Mar 6, 2025before open 65 8-K

What they guided beta

Q3 FY2026 "Reaffirmed full-year 2026 financial guidance" exhibit
Q3 FY2026 "We remain confident in our ability to meet our financial obligations and deliver on our full-year 2026 guidance.”" exhibit
Q3 FY2026 "The first subject has been dosed, and sites are currently enrolling across the U.S. Topline results are expected in the first quarter 2028." exhibit
Q3 FY2026 "Phathom expects to report topline results during the fourth quarter 2026 for the 12-week blinded treatment portion of its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA in patients with Eosinophilic Esophagitis (EoE)." exhibit
Q3 FY2026 "On October 23, 2026, FDA opened a public comment docket on issues raised in the litigation, with comments due November 23, 2026." exhibit
Q2 FY2026 "Updated full-year 2026 financial guidance" exhibit
Q2 FY2026 "“Our more moderate revenue guidance still reflects meaningful growth in the second half of 2026.”" exhibit
Q2 FY2026 "First subject enrollment for the planned Phase 3 trial is expected during the fourth quarter of 2026." exhibit
Q2 FY2026 "Topline results from the 12-week blinded treatment portion of the trial are expected during the fourth quarter of 2026." exhibit
Q2 FY2026 "The decrease of $31.2 million compared to the second quarter 2025 was attributable to cost savings associated with lower commercial promotional spend, lower personnel-related expenses, and lower third-party spend." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/PHAT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/PHAT

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

PHAT earnings date badge

HTML

<a href="https://veritasdata.dev/company/PHAT/"><img src="https://veritasdata.dev/embed/PHAT.svg" alt="PHAT earnings date" width="240" height="56"></a>

Markdown

[![PHAT earnings date](https://veritasdata.dev/embed/PHAT.svg)](https://veritasdata.dev/company/PHAT/)

Script

<script async src="https://veritasdata.dev/embed/PHAT.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/PHAT"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.